Ribupatide_Dosage, benefits & legal status
Also known as HRS9531, HRS-9531, KAI-9531, HRS 9531
An experimental weekly GLP-1/GIP shot from China, now in a 4,900-person phase 3 programme.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Ribupatide?
Plain language first. The technical label stays, but it never stands alone.Overview
It works the same two gut-hormone receptors as tirzepatide, with a slightly longer half-life and a higher dose ceiling. Phase 3 trials in China are complete and a global phase 3 programme finished enrolling in September 2026. It is not approved anywhere.
What it's used for
An experimental weekly shot for weight loss and type 2 diabetes that works like tirzepatide. Chinese phase 3 data show up to about 18% body weight lost at 48 weeks.
How does Ribupatide work?
What it does in the body, and where.Ribupatide is a 39-residue peptide that switches on both the GLP-1 and GIP receptors, the same pair tirzepatide works.
- 01GLP-1 receptorSlows stomach emptying, blunts appetite and improves the insulin response after meals. Kailera reports about three times tirzepatide's binding affinity here in cell assays.
- 02GIP receptorThe second incretin receptor, with about half tirzepatide's affinity in the same assays. The developer's design goal was a different balance between the two, not a new target.
- 03Fatty acid tailA 20-carbon fatty diacid on lysine 14 binds albumin and gives it a half-life of about 7 to 8 days, so one weekly shot holds the level.
Hits 2 receptors at once.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Weight loss
Investigational- Human trialChinese phase 3, 567 adults with obesity, 48 weeks: weight fell 10.7%, 16.4% and 17.7% at 2, 4 and 6 mg weekly against 1.4% on placebo (treatment-policy). 85.7% of the 6 mg group lost at least 5% and 44.4% lost at least 20%.
- Human trialChinese phase 2 at 8 mg, 61 adults, 36 weeks: 22.8% weight loss against 1.7% on placebo. The 23.6% figure often quoted is the supplementary hypothetical estimand from this same 49-person active group, not a phase 3 result.
- Human trialPhase 2 in women with obesity and polycystic ovary syndrome, 158 randomised, 32 weeks: 10.0%, 15.1% and 20.2% at 1, 2 and 4 mg against 2.6% on placebo.
Type 2 diabetes
Investigational- Human trialOpen-label Chinese phase 3 against semaglutide 1 mg, 884 adults on metformin, 36 weeks: HbA1c fell 2.78% at 4 mg and 2.34% at 2 mg against 2.29% on semaglutide. Non-inferiority was met and the 4 mg dose was statistically superior.
- Human trialPlacebo-controlled Chinese phase 3, 218 adults, 36 weeks: HbA1c fell up to 2.67%.
How it compares with tirzepatide
Early research- Lab studyKailera reports about three times tirzepatide's GLP-1 receptor binding affinity and half its GIP receptor affinity in cell assays, and a half-life about two days longer. These are the developer's in-vitro figures.
- No dataNo head-to-head trial against tirzepatide has been run. The only active comparator so far is semaglutide.
Three errors circulate. The 23.6% weight-loss figure is the supplementary estimand from a 49-person phase 2 at 8 mg, not a phase 3 result; the phase 3 maximum was 6 mg and gave 17.7%. The claim that its sequence is undisclosed is false: FDA's GSRS publishes all 39 residues. It is not approved in China; the application was accepted in September 2025 and no decision had been reported by July 2026. Do not confuse it with HRS-7535 (an oral small molecule) or HRS-4729 (a triple agonist), both from the same developer.
The published record
Papers and trials about Ribupatide
40 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
40 registered trials · none with posted results
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Ribupatide
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
About 7 to 8 days
How much, and do you cycle it?
The range, and whether you take breaks.2 up to 10 mg per week (trial doses), weekly. Not cycled in the trials Trial dose
Given continuously for the whole study period, 48 weeks in the Chinese phase 3 and 76 weeks in the global one, with the dose stepped up at the start. That is a ramp rather than a cycle, and no trial in this class built in a planned break.
How long does it stay in the body?
The half-life, and where the figure comes from.About 7 to 8 daysTrial protocol
Measured in people across three studies and two developers. The oral tablet form shows a similar 145 to 168 hours.
Source: Hengrui ADA 2023 poster 763-P (156 to 192 h); Kailera ADA 2026 poster (176 to 188 h); He et al., Diabetes Obes Metab 2026, DOI 10.1111/dom.71218
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized Ribupatide keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 21% charged residues, 44% hydrophobic. Base may help.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- A personal or family history of medullary thyroid cancer or MEN 2, the standard GLP-1 class exclusion used in its trials
- A history of pancreatitis
- Pregnancy or breastfeeding
- Anyone who wants established long-term safety data, because the longest completed trials ran 52 weeks
Stop and get help
- Severe stomach pain spreading to your back, a possible sign of pancreatitis
- Vomiting badly enough that you cannot keep fluids down
- Pain under the right ribs with fever or yellowing skin, since gallbladder events were recorded in its trials
- Spreading hives, swelling of the face or throat, or trouble breathing
Common effects
- Diarrhoea in roughly 30 to 36% of people on 2 to 6 mg over 48 weeks, against 7% on placebo
- Nausea in 16 to 27% and vomiting in 14 to 24%, both rising with dose
- Reduced appetite in about one in five
- Dose reductions for side effects in 11% at 4 mg and 20% at 6 mg
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Ribupatide approved?
And where the numbers on this page come from.No. Ribupatide is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked10 October 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesFDA GSRS substance record, ribupatide (UNII 58K8SFK97C)Hengrui, ObesityWeek 2025 poster, HRS9531-301 phase 3 in obesityHengrui, ADA and EASD 2025 posters, HRS9531-203 phase 2 (8 mg)Kailera Therapeutics, Q2 2026 results (12 Aug 2026)Kailera Therapeutics, ADA 2026 poster, KAI-9531 phase 1 single-dose studyKailera Therapeutics, Form S-1 (27 Mar 2026)ClinicalTrials.gov, KaiNETIC-1 (NCT07284875), KaiNETIC-2 (NCT07284901), KaiNETIC-3 (NCT07284979)Jiangsu Hengrui, SSE announcement 2026-103 (16 Jul 2026)He K et al., Diabetes, Obesity and Metabolism 2026, preclinical and first-in-human evaluation of ribupatide
What has happened recently
Not approved anywhere. Hengrui's marketing application for the injection was accepted by China's NMPA in September 2025, with no decision reported as of its July 2026 filing. Kailera's global phase 3 programme (KaiNETIC-1, -2 and -3) finished enrolling about 4,900 people in September 2026, with topline data guided for mid-2028. No US filing has been made.
You can compare this against the whole library, or read how to check a seller.
What else is like Ribupatide?
Others in GLP-1 agonists, side by side.If you're weighing Ribupatide, it's worth reading VK2735, Zovaglutide (ZT-002), and Retatrutide in the same class.
An experimental weekly GLP-1/GIP shot from China, now in a 4,900-person phase 3 programme.
- Dose
- 2 up to 10 mg per week (trial doses)
- How often
- Weekly
An experimental weight-loss compound in the tirzepatide family, as a shot or pill.
- Dose
- 2.5 up to 15 mg per week (start low, increase slowly)
- How often
- Weekly
An experimental once-a-month weight-loss shot.
- Dose
- 80 up to 160 mg per month (trial doses)
- How often
- Monthly
An experimental weekly shot with some of the biggest weight-loss numbers yet in trials.
- Dose
- 1 up to 12 mg per dose (start low, increase slowly)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- FDA GSRS substance record, ribupatide (UNII 58K8SFK97C)(2025)Full 39-residue sequence with three modifications: Aib at position 2, a C20 fatty diacid on lysine 14 through gamma-glutamate and two OEG spacers, and a C-terminal amide. Proposed INN list 133.
- Hengrui, ObesityWeek 2025 poster, HRS9531-301 phase 3 in obesity(2025)567 adults, 48 weeks, 2, 4 or 6 mg weekly versus placebo. Weight change up to 17.7% (treatment-policy) and 19.2% (hypothetical) at 6 mg; placebo 1.4%. Diarrhoea 30 to 36%, nausea 16 to 27%, vomiting 14 to 24%; dose reductions 11% at 4 mg and 20% at 6 mg.
- Hengrui, ADA and EASD 2025 posters, HRS9531-203 phase 2 (8 mg)(2025)61 adults, 36 weeks, titration to 8 mg over 24 weeks then 12 weeks at 8 mg. Weight change 22.8% versus 1.7% on placebo (treatment-policy); 23.6% on the supplementary hypothetical estimand. 49 people received the drug.
- Kailera Therapeutics, Q2 2026 results (12 Aug 2026)(2026)Chinese phase 3 in type 2 diabetes: HbA1c fell 2.78% at 4 mg and 2.34% at 2 mg versus 2.29% on semaglutide 1 mg at 36 weeks; non-inferiority met and 4 mg statistically superior. US phase 2b testing 10, 13, 16 and 20 mg weekly.
- Kailera Therapeutics, ADA 2026 poster, KAI-9531 phase 1 single-dose study(2026)Geometric mean half-life 176 to 188 hours across 1, 2 and 3 mg single doses in 49 adults. Escalation stopped at 3 mg after a nausea stopping rule was met; no serious adverse events.
- Kailera Therapeutics, Form S-1 (27 Mar 2026)(2026)Designed for a profile superior to tirzepatide: about 3x GLP-1 receptor and 0.5x GIP receptor binding affinity in vitro, half-life about seven days. States that no head-to-head trial against tirzepatide has been run.
- ClinicalTrials.gov, KaiNETIC-1 (NCT07284875), KaiNETIC-2 (NCT07284901), KaiNETIC-3 (NCT07284979)(2026)Three global phase 3 trials, 2,530, 1,270 and 1,270 participants, weekly doses of 4 to 10 mg over 76 weeks; KaiNETIC-3 includes an open-label semaglutide 2.4 mg arm. Primary completion estimated 2028.
- Jiangsu Hengrui, SSE announcement 2026-103 (16 Jul 2026)(2026)Marketing application for HRS9531 injection accepted by the NMPA in September 2025, no approval decision reported. Trial approval for obesity with knee osteoarthritis.
- He K et al., Diabetes, Obesity and Metabolism 2026, preclinical and first-in-human evaluation of ribupatide(2026)Peer-reviewed phase 1 report. Mean half-life 7 to 8 days in the multiple-dose part.
Beyond these, 41 records are indexed. Browse the records